Sanofi (SNY) Amortizatization of Intangibles (2024 - 2026)
Sanofi's (SNY) quarterly Amortizatization of Intangibles came in at -$626.3 million in Q1 2026, down 49.24% year-on-year from -$1.2 billion in Q1 2025, and up 69.7% quarter-over-quarter from -$2.1 billion in Q4 2025.
Sanofi (SNY) Amortizatization of Intangibles (2024 - 2026) Analysis & Trends
Sanofi has disclosed Amortizatization of Intangibles across 3 years of filings, most recently posting -$626.3 million for Q1 2026.
- Amortizatization of Intangibles for Q1 2026 came in at -$626.3 million, down 49.24% year-over-year; the trailing twelve-month figure through Mar 2026 was -$5.0 billion (changed N/A YoY), and the FY2025 annual result was -$2.1 billion, down 10.61% from the prior year.
- Amortizatization of Intangibles came in at -$626.3 million for Q1 2026 at Sanofi, up from -$2.1 billion in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of -$419.7 million in Q1 2025 to a low of -$2.1 billion in Q4 2025.
- The 3-year median for Amortizatization of Intangibles is -$1.2 billion (2026), against an average of -$1.2 billion.
- Across the five-year window, Amortizatization of Intangibles decreased 10.61% in 2025 and plunged 49.24% in 2026, its largest moves.
- Sanofi's Amortizatization of Intangibles stood at -$1.9 billion in 2024, then slipped by 10.61% to -$2.1 billion in 2025, then soared by 69.7% to -$626.3 million in 2026.
- The last three Amortizatization of Intangibles figures came in at -$626.3 million (Q1 2026), -$2.1 billion (Q4 2025), and -$419.7 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 1.70 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 931.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 596.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Sanofi | 63.47 Mn | -6.87 Bn | 9.49 Bn | -626.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -626.35 Mn |
| Mar 31, 2026 | -626.35 Mn |
| Dec 31, 2025 | -2.07 Bn |
| Dec 31, 2025 | -2.07 Bn |
| Mar 31, 2025 | -419.70 Mn |
| Mar 31, 2025 | -419.70 Mn |
| Dec 31, 2024 | -1.87 Bn |
| Dec 31, 2024 | -1.87 Bn |